Mibor 2mg Injection (Bortezomib Injection IP)

Mibor 2mg Injection is a chemotherapy medicine with active ingredient Bortezomib Injection IP. It belongs to the class of drug known as proteasome inhibitors. It is prescribed to treat multiple myeloma and mantle cell lymphoma.

It works by slowing or blocking the breakdown of proteins in cells to control the progression of cancer. It should be administered by a doctor or experienced nurse. Don't self administer the injection.

Multiple Myeloma, Mantle Cell Lymphoma

Mibor 2mg Injection(Bortezomib Injection IP) is a strong anticancer medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.
Some common side effects include:
● Pneumonia
● Loss of appetite
● Sensitivity, tingling and burning sensation of the skin
● Nausea, vomiting, and diarrhea
● Mouth ulcers
● Constipation
● Muscle and bone pain
● Hair loss
● Fever
● Reduction in blood cell count
● Reduced kidney function
● Shivering
● Infections
● Itching and redness
● Dehydration
● Stomach problems
● Difficulty sleeping, anxiety, mood swings, depressed mood

Dosage and duration with Mibor 2mg Injection are determined by the doctor as per the stage & type of cancer and overall health condition of the patient. Mibor(Bortezomib Injection IP) should be given intravenously by a doctor or experienced nurse. Don't self- administer the injection.

​● Bross, P. F., Kane, R., Farrell, A. T., Abraham, S., Benson, K., Brower, M. E., ... & Pazdur, R. (2004). Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clinical cancer research, 10(12), 3954-3964.
​● Dasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., ... & Grant, S. (2011). Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular cancer therapeutics, 10(9), 1686-1697.
​● Bross, P. F., Kane, R., Farrell, A. T., Abraham, S., Benson, K., Brower, M. E., ... & Pazdur, R. (2004). Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clinical cancer research, 10(12), 3954-3964.
​● Kane, R. C., Dagher, R., Farrell, A., Ko, C. W., Sridhara, R., Justice, R., & Pazdur, R. (2007). Bortezomib for the treatment of mantle cell lymphoma. Clinical cancer research, 13(18), 5291-5294.
​● Hambley, B., Caimi, P. F., & William, B. M. (2016). Bortezomib for the treatment of mantle cell lymphoma: an update. Therapeutic advances in hematology, 7(4), 196-208.​